AC 100

Drug Profile

AC 100

Alternative Names: AC-100; Dentonin; DTN

Latest Information Update: 28 Jul 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Acologix
  • Class Osteoporosis therapies; Peptide fragments
  • Mechanism of Action Dinoprostone modulators; Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Bone disorders; Cartilage disorders; Periodontal disorders

Highest Development Phases

  • Discontinued Bone disorders; Cartilage disorders; Periodontal disorders; Postmenopausal osteoporosis

Most Recent Events

  • 06 Mar 2010 AC 100 is still available for licensing (http://www.acologix.com)
  • 06 Mar 2010 No development reported - Phase-I for Postmenopausal osteoporosis in USA (SC)
  • 06 Mar 2010 Phase-I clinical trials in Bone disorders in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top